FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 642 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR A Systematic Analysis of the Global Burden of Disease from 2010... April 20, 2022 Cancer Researchers Bring Tools, Experience to COVID-19 Studies February 12, 2021 The director’s cut: How Dr Catherine Elliott sees the future of... November 2, 2021 EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan November 14, 2022 Load more HOT NEWS Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer... Group of Breast Cancer Survivors is Finding New Strength from Fitness... Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy? Dexrazoxane Protects the Heart Long Term for Kids Being Treated for...
